The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

This within-subject, double-blind, randomized crossover trial (n=30) tests whether AMPA receptor blockade with perampanel reduces ketamine's anti-suicidal and antidepressant effects in participants with MDD, bipolar disorder, or PTSD and current suicidal ideation.

Participants receive oral perampanel 6 mg or placebo 2.5 hours before a standard subanesthetic ketamine infusion (0.5 mg/kg over 40 minutes); infusions are separated by at least three weeks with follow-up assessments through interview and electronic diary.